NCT07215806View on ClinicalTrials.gov

Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

November 25, 2022

Study Completion Date

November 25, 2022

Conditions
Healthy
Interventions
DRUG

Evobruitnib

Participants received Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.

DRUG

Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]

Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15.

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY